A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Схожие документы

• THROMBOTIC THROMBOCYTOPENIC PURPURA
  по: Ali Rıza Odabaş, и др.
  Опубликовано: (2019-09-01)
• Vaccination and Thrombotic Thrombocytopenic Purpura
  по: İrfan Yavaşoğlu
  Опубликовано: (2020-08-01)
• Thrombotic thrombocytopenic purpura: much done, but still a lot to do
  по: Paola Binetti
  Опубликовано: (2024-08-01)
• A Case of Acquired Thrombotic Thrombocytopenic Purpura: Three Recurrences in 25 Years
  по: Şinasi Özsoylu
  Опубликовано: (2015-07-01)
• Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura
  по: Alev Akyol Erikçi, и др.
  Опубликовано: (2016-05-01)